Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics.

Company profile
Ticker
INCY
Exchange
Website
CEO
Herve Hoppenot
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
INCYTE GENOMICS INC, INCYTE INC, INCYTE PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Incyte Biosciences Corporation • Incyte Holdings Corporation • Incyte Research Institute LLC • Incyte International Holdings Corporation • Incyte Biosciences Canada Corporation • Incyte International Holdings • Incyte Biosciences International • Incyte Biosciences Austria GmbH • Incyte Biosciences Denmark ApS • Incyte Biosciences Germany GmbH ...
IRS number
943136539
INCY stock data
News

Approval Of Baricitinib For Patchy Baldness Validates Clinical Patch For This Small-Cap Stock
14 Jun 22
The Daily Biotech Pulse: FDA Nod For Lilly-Incyte's Patchy Hair Loss Treatment, First Regulatory Submission For EQRx, Soleno's Promising Data From Prader-Willi Candidate
14 Jun 22
Morning Brief: Top Financial Stories Dominating on Tuesday, June 14
14 Jun 22
Lilly-Incyte Snag FDA Nod For Patchy Hair Loss Treatment — Smaller Rival's Stock Shoots Up In Sympathy
14 Jun 22
Pfizer, MorphoSys And Incyte Enter Into Clinical Trial Collaboration For Monjuvi In Combination With TTI-622, A Fusion Protein Directed Against CD47
13 Jun 22
Press releases
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata
13 Jun 22
Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
13 Jun 22
Data from Incyte's Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
26 May 22
CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)
20 May 22
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19
11 May 22
Analyst ratings and price targets
Current price
Average target
$74.33
Low target
$58.00
High target
$88.00
Morgan Stanley
Maintains
$77.00
RBC Capital
Maintains
$88.00
SVB Leerink
Maintains
$58.00
Calendar
3 May 22
26 Jun 22
31 Dec 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Jun 22 | Otis W Brawley | Common Stock | Grant | Acquire A | No | No | 0 | 2,144 | 0 | 3,399 |
15 Jun 22 | Otis W Brawley | NQSO Common Stock | Grant | Acquire A | No | No | 68.55 | 9,124 | 625.45K | 9,124 |
15 Jun 22 | Fouse Jacqualyn A | Common Stock | Grant | Acquire A | No | No | 0 | 2,144 | 0 | 10,655 |
15 Jun 22 | Fouse Jacqualyn A | NQSO Common Stock | Grant | Acquire A | No | No | 68.55 | 9,124 | 625.45K | 9,124 |
15 Jun 22 | Clancy Paul J | Common Stock | Grant | Acquire A | No | No | 0 | 2,144 | 0 | 10,434 |
15 Jun 22 | Clancy Paul J | NQSO Common Stock | Grant | Acquire A | No | No | 68.55 | 9,124 | 625.45K | 9,124 |
15 Jun 22 | Harrigan Edmund | Common Stock | Grant | Acquire A | No | No | 0 | 2,144 | 0 | 7,716 |
15 Jun 22 | Harrigan Edmund | NQSO Common Stock | Grant | Acquire A | No | No | 68.55 | 9,124 | 625.45K | 9,124 |
15 Jun 22 | Jean Jacques Bienaime | Common Stock | Grant | Acquire A | No | No | 0 | 2,144 | 0 | 12,988 |
15 Jun 22 | Jean Jacques Bienaime | NQSO Common Stock | Grant | Acquire A | No | No | 68.55 | 9,124 | 625.45K | 9,124 |
Institutional ownership, Q1 2022
13F holders | Current |
---|---|
Total holders | 512 |
Opened positions | 65 |
Closed positions | 70 |
Increased positions | 184 |
Reduced positions | 187 |
13F shares | Current |
---|---|
Total value | 22.78B |
Total shares | 238.32M |
Total puts | 778K |
Total calls | 547.5K |
Total put/call ratio | 1.4 |
Largest owners | Shares | Value |
---|---|---|
Baker Bros. Advisors | 36.15M | $2.87B |
Baker Julian | 34.28M | $4.13B |
Vanguard | 20.89M | $1.66B |
BLK Blackrock | 18.09M | $1.44B |
Dodge & Cox | 18.06M | $1.43B |
Wellington Management | 9.34M | $741.64M |
STT State Street | 9.25M | $735.01M |
RY Royal Bank Of Canada | 7.68M | $610.16M |
Renaissance Technologies | 4.7M | $373.09M |
TROW T. Rowe Price | 4.69M | $372.66M |
Financial report summary
?Competition
Geron • CTI BioPharma • Exelixis • Curis • Infinity Pharmaceuticals • Lumos Pharma • Medicinova • Sierra Oncology • AVEO Pharmaceuticals • AnaptysBioManagement Discussion
- We recorded net income of $38.0 million and basic and diluted net income per share of $0.17 for the three months ended March 31, 2022, as compared to net income of $53.5 million and basic and diluted net income per share of $0.24 in the corresponding period in 2021.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
addressing, amplified, boxed, broader, Canadian, Carlo, certificate, chemical, confirmatory, crisaborole, Cyclin, defective, diagnostic, digit, dupilimab, DUPIXENT, eczema, enterprise, EUCRISA, forward, geopolitical, GMP, highlighted, idiopathic, instability, macroeconomic, merit, Monte, Montreal, MZL, neuropathy, NHL, NMPA, occupancy, Pfizer, phototherapy, prednisone, pulmonary, qualification, Regeneron, replication, resource, resourced, retaliatory, roll, Russia, Russian, safer, Sanofi, serine, shift, shrinkage, simulation, SRI, steroid, threonine, Ukraine, visitor, vivo
Removed:
absorb, accounted, aged, aging, agnostic, Aid, allocate, allocation, amortizable, amortize, amortized, analyzing, anniversary, Answer, approximate, approximation, assigned, ASU, attribution, attrition, Austrian, axial, bankruptcy, beginning, beneficiary, binary, borrowing, BRAVE, call, Celgene, channel, characteristic, classification, classify, clearance, closely, coincide, collateral, collectability, collected, combined, comparing, conclude, constrain, constrained, constraint, context, controlling, converted, coordinate, counterparty, CRO, custodial, deduct, deducted, depreciation, determinable, dictated, directing, discretion, dispensing, distinct, dividing, dollar, elapsed, eligibility, entirety, environment, examination, expensed, facilitate, feasible, fedratinib, finite, fiscal, fixed, fleet, function, functionality, German, governance, granting, guaranteed, identification, immaterial, inception, inclusion, INREBIC, intangible, Internet, invoiced, judged, judgement, largest, lessee, magnitude, marketability, measuring, mentioned, methodological, methodology, modification, monitored, Motion, mutually, noncurrent, nonrefundable, outset, outsourced, participant, participatory, partnership, payable, payroll, performed, performing, periodically, Pocket, point, predominant, prepaid, prepare, prepay, prepayment, priced, print, printing, professional, progression, protective, prudent, psoriatic, quantitative, radio, realization, recognizing, recoverability, redemption, reliable, relief, renamed, reportable, reputable, residual, Restated, restrictive, retail, reversal, revert, reverting, reviewed, revised, Rodino, rollforward, running, satisfied, sector, secure, setup, shelf, sheltered, shipping, Simplifying, spending, Squibb, standalone, stimulate, subordinated, substantive, taxable, technical, television, thereon, Topic, transferred, transferring, translated, translating, trillion, TrOOP, true, uncured, undiscounted, unpaid, unusual, valid, variable, VIE, voting, waiting, waived, weighting, writing, written
Financial reports
Current reports
8-K
Submission of Matters to a Vote of Security Holders
16 Jun 22
8-K
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key
3 May 22
8-K
Departure of Directors or Certain Officers
21 Apr 22
8-K
Incyte Reports 2021 Fourth Quarter and Year-end Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs
8 Feb 22
8-K
Departure of Directors or Certain Officers
14 Jan 22
8-K
Corporate Statement Regarding Opzelura™ (ruxolitinib) Cream
2 Nov 21
8-K
Incyte Reports 2021 Third Quarter Financial Results
2 Nov 21
8-K
Departure of Directors or Certain Officers
28 Sep 21
8-K
Entry into a Material Definitive Agreement
20 Aug 21
8-K
Incyte Reports 2021 Second Quarter Financial Results
3 Aug 21
Registration and prospectus
S-3ASR
Automatic shelf registration
8 Feb 22
S-8
Registration of securities for employees
11 Jun 21
S-8
Registration of securities for employees
15 Jun 20
S-8
Registration of securities for employees
30 Apr 19
S-3ASR
Automatic shelf registration
14 Feb 19
S-8
Registration of securities for employees
24 May 18
424B2
Prospectus for primary offering
10 Sep 17
424B3
Prospectus supplement
7 Sep 17
424B7
Prospectus with selling stockholder info
9 Mar 17
S-8
Registration of securities for employees
16 Jun 16
Proxies
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEFA14A
Additional proxy soliciting materials
14 May 21
DEFA14A
Additional proxy soliciting materials
16 Apr 21
DEFA14A
Additional proxy soliciting materials
14 May 20
PX14A6G
Letter to shareholders
24 Apr 20
DEF 14A
Definitive proxy
20 Apr 20
DEFA14A
Additional proxy soliciting materials
22 Apr 19
PX14A6G
Letter to shareholders
1 Apr 19
Other
UPLOAD
Letter from SEC
12 Apr 20
CORRESP
Correspondence with SEC
6 Apr 20
UPLOAD
Letter from SEC
24 Mar 20
CT ORDER
Confidential treatment order
7 Nov 19
CT ORDER
Confidential treatment order
7 Nov 19
CT ORDER
Confidential treatment order
7 Nov 19
CT ORDER
Confidential treatment order
7 Nov 19
CT ORDER
Confidential treatment order
7 Nov 19
CORRESP
Correspondence with SEC
28 Mar 19
UPLOAD
Letter from SEC
28 Mar 19
Ownership
4
INCYTE / JULIAN BAKER ownership change
17 Jun 22
4
INCYTE / JACQUALYN A FOUSE ownership change
17 Jun 22
4
INCYTE / Paul J Clancy ownership change
17 Jun 22
4
INCYTE / Katherine A High ownership change
17 Jun 22
4
INCYTE / EDMUND HARRIGAN ownership change
17 Jun 22
4
INCYTE / JEAN JACQUES BIENAIME ownership change
17 Jun 22
4
INCYTE / OTIS W BRAWLEY ownership change
17 Jun 22
4
INCYTE / Maria E Pasquale ownership change
12 Apr 22
4
INCYTE / Barry P Flannelly ownership change
12 Apr 22
4
INCYTE / JULIAN BAKER ownership change
4 Apr 22
Patents
Utility
Oral Formulation for a PD-L1 Inhibitor
23 Jun 22
Disclosed are oral formulations for a compound which modulates PD-1/PD-L1 protein/protein interaction, or a pharmaceutically acceptable salt thereof, which do not require cold chain storage.
Utility
Heterocyclic Compounds As Immunomodulators
23 Jun 22
Inventors: Liangxing Wu, Jingwei Li, Chao Qi, Fenglei Zhang, Zhenwu Li, Wenyu Zhu, Zhiyong Yu, Kaijiong Xiao, Liang Lu, Song Mei, Ding-Quan Qian, Chunhong He, Yingda Ye, Meizhong Xu, Wenqing Yao
Utility
ANTI-CD19 Combination Therapy
16 Jun 22
The present disclosure is directed to a therapeutic combination of an anti-CD19 antibody and R-CHOP or an anti-CD19 antibody, lenalidomide, and R-CHOP for use in the treatment of diffuse large B cell lymphoma.
Utility
JAK1 Pathway Inhibitors for the Treatment of Vitiligo
9 Jun 22
This disclosure relates to JAK1 pathway inhibitors and their use in treating vitiligo.
Utility
Bicyclic Heteroarylaminoalkyl Phenyl Derivatives As PI3K Inhibitors
9 Jun 22
Inventors: Yun-Long Li, Andrew P. Combs
Transcripts
2022 Q1
Earnings call transcript
3 May 22
2021 Q4
Earnings call transcript
8 Feb 22
2021 Q3
Earnings call transcript
2 Nov 21
2021 Q2
Earnings call transcript
3 Aug 21
2021 Q1
Earnings call transcript
4 May 21
2021 Q1
Earnings call transcript
4 May 21
2020 Q4
Earnings call transcript
9 Feb 21
2020 Q3
Earnings call transcript
5 Nov 20
2020 Q2
Earnings call transcript
4 Aug 20
2020 Q1
Earnings call transcript
5 May 20
Reddit threads
229 S&P500 companies ($21.6t in market cap, 61.8%) report earnings in the next ~30 days
25 Jun 22
What is up with these hedge fund held stocks???
18 May 22
Sort of a binary play (GERN)
14 May 22
(5/3) Tuesday's Pre-Market Stock Movers & News
3 May 22
Daily Discussion Thread - May 3rd, 2022
3 May 22
Daily Discussion Thread - May 2nd, 2022
2 May 22
I think I need exposure to other sectors?
28 Apr 22
Bull/bear case for these companies? (MU, AMAT, TER, SEIC, INMD, INCY)
8 Mar 22
What are the most reliable sources (sites/apps) to screen companies? (plus some companies with good financials)
7 Mar 22
Daily Discussion Thread - February 8th, 2022
8 Feb 22